Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
great DD ceo has done a great job
https://twitter.com/Charlie35911/status/1744345073376968897?t=x0tvLlAYZ_mLmFX_DNi2kg&s=19
Fridays Darkpool
Off-Exchange Short Volume 19,517,949 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 62.98 % - source: FINRA (inc. Dark Pool volume)
Finpedia Article Rennova Health
🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡
Big business coming to RNVA More than 15.3 million Americans have signed up for health insurance under the Affordable Care Act (ACA) for 2024, a 33% increase from this time last year, according to data released by the Centers for Medicare & Medicaid Services.
great DD just posted GO RNVA
https://twitter.com/Charlie35911/status/1743330510883938540?t=f1xL1O-nAvn3fOf6MoiCCg&s=19
REMEMBER CEO HAS THE CASH TO BUY SHARES BACK $$$$$$$$$$$$$🤑
Smart investors love companies that produce plenty of free cash flow (FCF). It signals a company's ability to pay down debt, pay dividends, buy back stock, and facilitate the growth of the business.
Go RNVA CEO HAS DONE A GREAT JOB
Checkout the Free cash flow
Further, companies that generate the free cash flow (FCF) required to steadily buy back their shares often have the dominant market share and pricing power required to boost the bottom line.
RNVA
free cash flow of $3.73 million.🤑🤑🤑🤑
Hey DO BEARS SHIT IN THE WOODS LOL 😋
Margins 🤑
Gross margin is 63.10%, with operating and profit margins of 17.96% and 11.66%.
Gross Margin 63.10%
Operating Margin 17.96%
Pretax Margin 14.83%
Profit Margin 11.66%
EBITDA Margin 24.45%
EBIT Margin 22.63%
FCF Margin 18.36%
Rennova Health had revenue of $20.30M in the twelve months ending September 30, 2023, with 113.44% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $3.54M with 25.20% year-over-year growth. In the year 2022, Rennova Health had annual revenue of $13.04M with 304.36% growth.
🤑🤑🤑🤑🤑🤑🤑🤑🤑
Revenue (ttm)
$20.30M
Revenue Growth
+113.44%
P/S Ratio
0.20
Revenue / Employee
$238,855
Employees
85
Market Cap
4.06M USD
Yup
RNVA FCF Yield 91.90% 🤑🤑🤑🤑🤑🤑
KEY TAKEAWAYS
A higher free cash flow yield is ideal because it means a company has enough cash flow to satisfy all of its obligations.
If the free cash flow yield is low, it means investors aren't receiving a very good return on the money they're investing in the company.
The free cash flow yield gives investors an idea of how financially capable a company is at having quick access to cash in case of unexpected debts or other obligations, or how much cash would be available if the company had to be liquidated.
Dividends & Yields
Rennova Health does not appear to pay any dividends at this time.
Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield 58.36%
FCF Yield 91.90%
No REVERSE SPLIT FACTS 😉🤑
Lagan stated that there were approximately two hundred and fifty billion shares authorized meaning that there was no need for a reverse split for the foreseeable future. He confirmed that the Company currently had no plans to complete a reverse split.
To hear Seamus Lagan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/8157101-rennova-health-inc-provides-update-to-the-stock-day-podcast.
Net Revenues 🤑
Net revenues were $14.8 million for the nine months ended September 30, 2023, as compared to $7.6 million for the nine months ended September 30, 2022, an increase of $7.3 million. We attribute the increase in net revenues to greater inpatient admissions, increased outpatient and emergency room services, higher reimbursement rates and certain collections from prior periods related to Critical Access Hospital designation at our Big South Fork Medical Center. We began billing as a Critical Access Hospital in the three months ended June 30, 2022 retroactive to June 30, 2021.
WEST PALM BEACH, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA) is pleased to announce a significant debt restructuring with its primary institutional investors. The restructuring extends the maturity date of approximately $8.2 million of secured debt to December 31, 2025, waives historical events of default and removes and/or modifies certain events of default and definitions. In addition, the Company does not expect to recognize default interest in future periods subject to remaining in compliance with covenants and other obligations.
“We are pleased in the confidence our primary institutional investors have in our Company and its recent achievements,” commented Seamus Lagan, Chief Executive Officer of Rennova. “The debt restructuring improves our balance sheet and will save approximately $1.5 million in interest expense annually.🤑🤑🤑🤑🤑
About
Currently the CEO of Rennova Health, Inc.
More information at www.rennovahealth.com
Restructured Medytox Solutions, Inc. in mid 2011 and oversaw the growth from less than $1M of sales per year to approximately $57M of reported sales in 2014. Completed merger with CollabRx, Inc. in 2015 to create Nasdaq listed Rennova Health, Inc. (RNVA) in November 2015. Redirected business model from diagnostics to rural hospital development and acquisition in 2017 after significant disruption in the diagnostics sector.
Over 20 years’ experience in the development, restructuring, acquisition and management of startup and small companies in various sectors from alternative energy, oil and gas production and exploration, mining and healthcare. Provides services for both private and public companies. Has an extensive network of legal, accounting and other professional advisers that can be relied on to assist when required. Has numerous funding sources in different sectors to approach if required for qualifying projects. Has secured and structured millions of dollars in funding for various projects, including in excess of $30M in equity funding and approximately $20M of debt in 2015 and 2016 and a further $20M of investment in 2017. Main focus is acquisition and mergers of synergistic business with an emphasis on revenue and a sustainable business model to create long term value.
RNVA 🤑
Gross margin is 63.10%, with operating and profit margins of 17.96% and 11.66%.
Gross Margin 63.10%
Operating Margin 17.96%
Pretax Margin 14.83%
Profit Margin 11.66%
EBITDA Margin 24.45%
EBIT Margin 22.63%
FCF Margin 18.36%
RNVA FCF Yield 91.90% 🤑🤑🤑🤑🤑🤑
KEY TAKEAWAYS
A higher free cash flow yield is ideal because it means a company has enough cash flow to satisfy all of its obligations.
If the free cash flow yield is low, it means investors aren't receiving a very good return on the money they're investing in the company.
The free cash flow yield gives investors an idea of how financially capable a company is at having quick access to cash in case of unexpected debts or other obligations, or how much cash would be available if the company had to be liquidated.
Dividends & Yields
Rennova Health does not appear to pay any dividends at this time.
Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield 58.36%
FCF Yield 91.90%
Dont forget
Yesterdays Darkpool BEARS
Off-Exchange Short Volume 275,176,464 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 60.37 % -
source: FINRA (inc. Dark Pool volume)
Finpedia Article Rennova Health
P.S THIS WHY ALL THE TRASH TALKERS 🤣🤣🤣
dont let the BEARS fool you there's NAKEDSHORTS GO RNVA
https://twitter.com/Charlie35911/status/1743098122710970702?t=WHY1_-xoL4RH-mKahpJuqA&s=19
Yesterdays Darkpool BEARS
Off-Exchange Short Volume 275,176,464 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 60.37 % -
source: FINRA (inc. Dark Pool volume)
Finpedia Article Rennova Health
P.S THIS WHY ALL THE TRASH TALKERS 🤣🤣🤣
RNVA FCF Yield 91.90% 🤑🤑🤑🤑🤑🤑
KEY TAKEAWAYS
A higher free cash flow yield is ideal because it means a company has enough cash flow to satisfy all of its obligations.
If the free cash flow yield is low, it means investors aren't receiving a very good return on the money they're investing in the company.
The free cash flow yield gives investors an idea of how financially capable a company is at having quick access to cash in case of unexpected debts or other obligations, or how much cash would be available if the company had to be liquidated.
Dividends & Yields
Rennova Health does not appear to pay any dividends at this time.
Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield 58.36%
FCF Yield 91.90%
RNVA
Gross margin is 63.10%, with operating and profit margins of 17.96% and 11.66%.
Gross Margin 63.10%
Operating Margin 17.96%
Pretax Margin 14.83%
Profit Margin 11.66%
EBITDA Margin 24.45%
EBIT Margin 22.63%
FCF Margin 18.36%
No REVERSE SPLIT FACTS 😉🤑
Lagan stated that there were approximately two hundred and fifty billion shares authorized meaning that there was no need for a reverse split for the foreseeable future. He confirmed that the Company currently had no plans to complete a reverse split.
To hear Seamus Lagan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/8157101-rennova-health-inc-provides-update-to-the-stock-day-podcast.
About
Currently the CEO of Rennova Health, Inc.
More information at www.rennovahealth.com
Restructured Medytox Solutions, Inc. in mid 2011 and oversaw the growth from less than $1M of sales per year to approximately $57M of reported sales in 2014. Completed merger with CollabRx, Inc. in 2015 to create Nasdaq listed Rennova Health, Inc. (RNVA) in November 2015. Redirected business model from diagnostics to rural hospital development and acquisition in 2017 after significant disruption in the diagnostics sector.
Over 20 years’ experience in the development, restructuring, acquisition and management of startup and small companies in various sectors from alternative energy, oil and gas production and exploration, mining and healthcare. Provides services for both private and public companies. Has an extensive network of legal, accounting and other professional advisers that can be relied on to assist when required. Has numerous funding sources in different sectors to approach if required for qualifying projects. Has secured and structured millions of dollars in funding for various projects, including in excess of $30M in equity funding and approximately $20M of debt in 2015 and 2016 and a further $20M of investment in 2017. Main focus is acquisition and mergers of synergistic business with an emphasis on revenue and a sustainable business model to create long term value.
Rennova Health had revenue of $20.30M in the twelve months ending September 30, 2023, with 113.44% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $3.54M with 25.20% year-over-year growth. In the year 2022, Rennova Health had annual revenue of $13.04M with 304.36% growth.
i have a great feeling about RNVA 2024 Americans' physical and mental health are suffering more than before the pandemic, per Axios.
🤑🤑🤑🤑🤑 myrtlerecoverycenters
Davis then mentioned the fast approaching year end and suggested that the Company could be leaving 2023 with annualized revenues in the $25-30 million range and be profitable. He asked Lagan how he intended to deliver continued growth and where he saw the Company a year from now.
Lagan responded that the current operations plus the behavioral health business should give the Company an annualized run rate of $25-30 million by year end. He went on to remind Davis that there were still some items to be fixed from previous more difficult days but explained the intention to formulate a plan before year end to duplicate the current model in the Jamestown facility in 2024, and stated that if that was successful it would be possible to leave 2024 with annualized revenues of $50-60 million. He confirmed his belief that this was achievable.
Davis ended the interview by asking Lagan what message he would like the Company’s shareholders to take away from the interview. Lagan responded by saying that he believed the Company was now delivering what it had hoped to deliver from work done over the past couple of years and stated a belief that there will be continued success and growth over the next couple of years.
To hear Seamus Lagan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/8351331-rennova-health-inc-is-featured-on-the-stock-day-podcast
Rennova Health had revenue of $20.30M in the twelve months ending September 30, 2023, with 113.44% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $3.54M with 25.20% year-over-year growth. In the year 2022, Rennova Health had annual revenue of $13.04M with 304.36% growth.
RNVA Margins
Gross margin is 63.10%, with operating and profit margins of 18.18% and 11.66%.
Gross Margin 63.10%
Operating Margin 18.18%
Pretax Margin 16.69%
Profit Margin 11.66%
EBITDA Margin 21.27%
EBIT Margin 19.45%
FCF Margin 18.02%
RNVA
free cash flow of $3.73 million.
CEO HAS CASH TO BUY SHARES BACK
Income Statement 🤑
In the last 12 months, Rennova Health had revenue of $20.30 million and earned $2.37 million in profits. Earnings per share was $0.05.
Revenue 20.30M
Gross Profit 12.81M
Operating Income 3.65M
Pretax Income 3.01M
Net Income 2.37M
EBITDA 4.96M
EBIT 4.60M
Earnings Per Share (EPS) $0.05
About
Currently the CEO of Rennova Health, Inc.
More information at www.rennovahealth.com
Restructured Medytox Solutions, Inc. in mid 2011 and oversaw the growth from less than $1M of sales per year to approximately $57M of reported sales in 2014. Completed merger with CollabRx, Inc. in 2015 to create Nasdaq listed Rennova Health, Inc. (RNVA) in November 2015. Redirected business model from diagnostics to rural hospital development and acquisition in 2017 after significant disruption in the diagnostics sector.
Over 20 years’ experience in the development, restructuring, acquisition and management of startup and small companies in various sectors from alternative energy, oil and gas production and exploration, mining and healthcare. Provides services for both private and public companies. Has an extensive network of legal, accounting and other professional advisers that can be relied on to assist when required. Has numerous funding sources in different sectors to approach if required for qualifying projects. Has secured and structured millions of dollars in funding for various projects, including in excess of $30M in equity funding and approximately $20M of debt in 2015 and 2016 and a further $20M of investment in 2017. Main focus is acquisition and mergers of synergistic business with an emphasis on revenue and a sustainable business model to create long term value.
No REVERSE SPLIT FACTS 😉🤑
Lagan stated that there were approximately two hundred and fifty billion shares authorized meaning that there was no need for a reverse split for the foreseeable future. He confirmed that the Company currently had no plans to complete a reverse split.
To hear Seamus Lagan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/8157101-rennova-health-inc-provides-update-to-the-stock-day-podcast.
Net Revenues
Net revenues were $14.8 million for the nine months ended September 30, 2023, as compared to $7.6 million for the nine months ended September 30, 2022, an increase of $7.3 million. We attribute the increase in net revenues to greater inpatient admissions, increased outpatient and emergency room services, higher reimbursement rates and certain collections from prior periods related to Critical Access Hospital designation at our Big South Fork Medical Center. We began billing as a Critical Access Hospital in the three months ended June 30, 2022 retroactive to June 30, 2021.
WEST PALM BEACH, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA) is pleased to announce a significant debt restructuring with its primary institutional investors. The restructuring extends the maturity date of approximately $8.2 million of secured debt to December 31, 2025, waives historical events of default and removes and/or modifies certain events of default and definitions. In addition, the Company does not expect to recognize default interest in future periods subject to remaining in compliance with covenants and other obligations.
“We are pleased in the confidence our primary institutional investors have in our Company and its recent achievements,” commented Seamus Lagan, Chief Executive Officer of Rennova. “The debt restructuring improves our balance sheet and will save approximately $1.5 million in interest expense annually.🤑🤑🤑🤑🤑
RNVA closed unchanged on Tuesday, January 2, 2024, on 2.89 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
YUP
Yesterdays Darkpool
Off-Exchange Short Volume 157,081,737 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 62.96 % - source: FINRA (inc. Dark Pool volume)
Finpedia Article Rennova Health
BEARS ALWAYS CALL STOCKS A SCAM 🤣🤣🤣
ALOT OF THINGS DONT MAKE SINCE BEARS BEEN STATING THIS FOR MONTHS ON END THERE WAS NO PRE-14C RITE BEAR LOL LOL LIAR hey RNVA May 23 bro get over it there was no PRE-14C FILED about R/S by the SEC that is not true why did you say it was released? VERY MISLEADING sorry ceo has done a great job.
NOBODY BELIEVES THE BEARS BULLSH$T I MEAN NO ONE FACTS YES THERE IS FREECASHFLOW AND NO R/S been hearing the same R/S THEORY MONTH'S ON END AND NOTHING LOL
BEEN MISLEADING SHAREHOLDERS THIS WHOLE TIME GO TO SHOW HOW THE BEARS WORK LOL LOL 🤣
P.s and still no R/S 🤣🤣🤣
Yesterdays Darkpool
Off-Exchange Short Volume 157,081,737 shares - source: FINRA (inc. Dark Pool volume)
Off-Exchange Short Volume Ratio 62.96 % - source: FINRA (inc. Dark Pool volume)
Finpedia Article Rennova Health
Net Revenues
Net revenues were $14.8 million for the nine months ended September 30, 2023, as compared to $7.6 million for the nine months ended September 30, 2022, an increase of $7.3 million. We attribute the increase in net revenues to greater inpatient admissions, increased outpatient and emergency room services, higher reimbursement rates and certain collections from prior periods related to Critical Access Hospital designation at our Big South Fork Medical Center. We began billing as a Critical Access Hospital in the three months ended June 30, 2022 retroactive to June 30, 2021.
WEST PALM BEACH, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA) is pleased to announce a significant debt restructuring with its primary institutional investors. The restructuring extends the maturity date of approximately $8.2 million of secured debt to December 31, 2025, waives historical events of default and removes and/or modifies certain events of default and definitions. In addition, the Company does not expect to recognize default interest in future periods subject to remaining in compliance with covenants and other obligations.
“We are pleased in the confidence our primary institutional investors have in our Company and its recent achievements,” commented Seamus Lagan, Chief Executive Officer of Rennova. “The debt restructuring improves our balance sheet and will save approximately $1.5 million in interest expense annually.🤑🤑🤑🤑🤑
Rennova Health had revenue of $20.30M in the twelve months ending September 30, 2023, with 113.44% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $3.54M with 25.20% year-over-year growth. In the year 2022, Rennova Health had annual revenue of $13.04M with 304.36% growth.
RNVA Margins
Gross margin is 63.10%, with operating and profit margins of 18.18% and 11.66%.
Gross Margin 63.10%
Operating Margin 18.18%
Pretax Margin 16.69%
Profit Margin 11.66%
EBITDA Margin 21.27%
EBIT Margin 19.45%
FCF Margin 18.02%
RNVA
free cash flow of $3.73 million.
CEO HAS CASH TO BUY SHARES BACK
Income Statement 🤑
In the last 12 months, Rennova Health had revenue of $20.30 million and earned $2.37 million in profits. Earnings per share was $0.05.
Revenue 20.30M
Gross Profit 12.81M
Operating Income 3.65M
Pretax Income 3.01M
Net Income 2.37M
EBITDA 4.96M
EBIT 4.60M
Earnings Per Share (EPS) $0.05
About
Currently the CEO of Rennova Health, Inc.
More information at www.rennovahealth.com
Restructured Medytox Solutions, Inc. in mid 2011 and oversaw the growth from less than $1M of sales per year to approximately $57M of reported sales in 2014. Completed merger with CollabRx, Inc. in 2015 to create Nasdaq listed Rennova Health, Inc. (RNVA) in November 2015. Redirected business model from diagnostics to rural hospital development and acquisition in 2017 after significant disruption in the diagnostics sector.
Over 20 years’ experience in the development, restructuring, acquisition and management of startup and small companies in various sectors from alternative energy, oil and gas production and exploration, mining and healthcare. Provides services for both private and public companies. Has an extensive network of legal, accounting and other professional advisers that can be relied on to assist when required. Has numerous funding sources in different sectors to approach if required for qualifying projects. Has secured and structured millions of dollars in funding for various projects, including in excess of $30M in equity funding and approximately $20M of debt in 2015 and 2016 and a further $20M of investment in 2017. Main focus is acquisition and mergers of synergistic business with an emphasis on revenue and a sustainable business model to create long term value.
No REVERSE SPLIT FACTS 😉🤑
Lagan stated that there were approximately two hundred and fifty billion shares authorized meaning that there was no need for a reverse split for the foreseeable future. He confirmed that the Company currently had no plans to complete a reverse split.
To hear Seamus Lagan’s entire interview, follow the link to the podcast here:
https://audioboom.com/posts/8157101-rennova-health-inc-provides-update-to-the-stock-day-podcast.
RNVA closed unchanged on Tuesday, January 2, 2024, on 2.89 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.